fosfomycin (monurol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Fosfomycin (marketed under the trade names Monurol and Monuril) is a broad-spectrum antibiotic. Monurol (fosfomycin tromethamine) sachet contains fosfomycin tromethamine, a synthetic, broad spectrum, bactericidal antibiotic for oral administration. Monurol is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis. Fosfomycin is a phosphoenolpyruvate analogue produced by Streptomyces that irreversibly inhibits enolpyruvate transferase (MurA), which prevents the formation of N-acetylmuramic acid, an essential element of the peptidoglycan cell wall.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$54.8800 - $87.5947
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(-)-(1r,2s)-(1,2-epoxypropyl)phosphonic acid | (1r,2s)-epoxypropylphosphonic acid | 1r-cis-(1,2-epoxypropyl)phosphonic acid | (2r-cis)-(3-methyloxiranyl)phosphonic acid | cis-(1r,2s)-epoxypropylphosphonic acid | combination of fosfomycin, metronidazole and rhgm-csf (administered together intraperitoneally) and three days of antibiotics p.o. | fcm | fosfocina | fosfomicina | fosfomycin | fosfomycin calcium | fosfomycine | fosfomycin sodium | fosfomycin trometamol | fosfomycin tromethamine | fosfomycinum | l-cis-1,2-epoxypropylphosphonic acid | monuril | monurol | phosphomycin | phosphomycin disodium | phosphonemycin | phosphonomycin | sodium fosfomycin | z-1282

Organizations (63)

Research & Development (59)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (35)

Approved Indications (2)


 

Cystitis (approved 1996)

Prostatitis

Experimental Indications - Clinical Trial Phases 1-4 (34)


 

Appendicitis (Phase 2)

Bacterial Infections (Phase 1)

Bacteriuria (Phase 4)

Brain Injuries (Phase 1)

Colonic Diseases (Phase 2)

Colonic Neoplasms (Phase 2)

Cystic Fibrosis (Phase 2)

Cystitis (Phase 4)

Drug Resistance, Bacterial (Phase 4)

Endocarditis (Phase 4)

Escherichia coli Infections (Phase 3)

Febrile Neutropenia (Phase 3)

Gonorrhea (Phase 3)

Graft Rejection (Phase 4)

Healthy Volunteers (Phase 1)

Hospitalization (Phase 4)

Infections (Phase 4)

Leukemia, Lymphoid (Phase 1)

Methicillin-Resistant Staphylococcus aureus (Phase 3)

Neonatal Sepsis (Phase 2)

Neoplasms (Phase 2/Phase 3)

Pharmacological and Toxicological Phenomena (Phase 3)

Pneumonia, Bacterial (Phase 2)

Pouchitis (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 4)

Prosthesis-Related Infections (Phase 4)

Pseudomonas Infections (Phase 1)

Pyelonephritis (Phase 2/Phase 3)

Staphylococcal Infections (Phase 4)

Urinary Bladder Neoplasms (Phase 2)

Urinary Bladder, Neurogenic (Phase 4)

Urinary Tract Infections (Phase 4)

Urological Manifestations (Phase 1/Phase 2)

Urologic Surgical Procedures (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial Organizations: 59

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue